Agreement Sets Stage for Collaborative Research with World-Class Academic Research Institutions
ALEXANDRIA, VA (February 25, 2025) – HyperSpectral, the world’s first AI-powered spectral intelligence company with hardware-agnostic solutions for target detection, announced a Memorandum of Understanding (MOU) with Stanford University and Case Western Reserve University. The MOU will guide collaborative efforts to develop HyperSpectral’s TB QuickDetect product and establish working relationships with FEND-TB and the R2D2 TB Network to drive innovation in tuberculosis (TB) diagnostics.
The MOU focuses on collaborative research to develop and commercialize TB QuickDetect — an innovative, low-cost and portable diagnostic tool for rapidly detecting tuberculosis and its drug-resistant strains. The initiative will be undertaken with FEND-TB, a FIND program conducting international TB research and diagnostics, as well as the R2D2 TB Network, a leader in developing better tests to diagnose TB. HyperSpectral will leverage FEND and R2D2’s expertise in diagnostic development, clinical testing and global implementation to help bring TB QuickDetect to underserved regions.
“We’re excited to partner with Stanford, Case Western, FEND and R2D2 — four premier organizations known for their leadership in scientific and global health innovation,” said Matt Theurer, co-founder and CEO of HyperSpectral. “Tuberculosis is a disease that severely impacts millions of people around the globe, TB QuickDetect could bring a step function change in combatting the bacteria by quickly identifying its presence and drug resistance. These new partnerships, along with FEND and R2D2’s interest and expertise, are fundamental to the development of TB QuickDetect, and we are thrilled to move forward.”
Since its founding in 2022, HyperSpectral has pioneered faster, more efficient, and cost-effective diagnostic solutions by integrating spectroscopy and artificial intelligence. This approach serves diverse industries—including food safety, health care, and defense—by improving the speed and accuracy of critical tests. HyperSpectral’s SpecAI™ technology measures the unique spectral fingerprints of different particles and combines those measurements with AI models trained on a variety of owned, third-party, and custom datasets. The result is rapid, non-intrusive detection of pathogens and other threats, helping to revolutionize the future of diagnostic testing.
About HyperSpectral
Based in Alexandria, VA, HyperSpectral seeks to combine spectroscopy, AI and machine learning to illuminate invisible threats. HyperSpectral is actively working to provide the defense industry and agricultural and medical technology sectors with real-time intelligence on product safety and protect people from invisible threats. For more information, visit https://www.hyperspectral.ai/.